News Alert: Zynga Inc. (NASDAQ:ZNGA), Nokia Corporation (ADR) (NYSE:NOK), AbbVie Inc. (NYSE:ABBV), GlaxoSmithKline plc (ADR) (NYSE:GSK), Abakan Inc. (OTCMKTS:ABKI)

Zynga Inc. (NASDAQ:ZNGA) a leading social game developer, announced that its Chief Executive Officer Don Mattrick will present at the Bank of America Merrill Lynch 2014 Global Technology Conference in San Francisco. The session is scheduled for Wednesday, June 4, 2014, at 2:05 p.m. Pacific Time (5:05 p.m. Eastern Time). Zynga Inc. (NASDAQ:ZNGA) net profit margin is -13.20% and weekly performance is -3.69%. On last trading day company shares ended up $3.39. Analysts mean target price for the company is $4.65. Zynga Inc. (NASDAQ:ZNGA) distance from 50-day simple moving average (SMA50) is -20.84%.

Nokia (NYSE:NOK) shares closed trading up 5.1% on Wednesday following an upgrade to “buy” from “hold” by analysts at Jefferies (JEF). Nokia Corporation (ADR) (NYSE:NOK) shares advanced 5.10% in last trading session and ended the day on $7.62. NOK gross Margin is 42.10% and its return on assets is -4.50%.Nokia Corporation (ADR) (NYSE:NOK) quarterly performance is 4.24%.

AbbVie Inc. (NYSE:ABBV) announced that its drug, Humira, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis (rare but serious inflammatory diseases of the eye). AbbVie Inc. (NYSE:ABBV) shares moved down -0.50% in last trading session and was closed at $53.27, while trading in range of $53.10 – $53.84. AbbVie Inc. (NYSE:ABBV) year to date (YTD) performance is 2.58%.

GlaxoSmithKline (NYSE:GSK) and partner Genmab announced disappointing data on their oncology drug, Arzerra. GlaxoSmithKline plc (ADR) (NYSE:GSK) ended the last trading day at $55.32. Company weekly volatility is calculated as 0.70% and price to cash ratio as 22.20.GlaxoSmithKline plc (ADR) (NYSE:GSK) showed a positive weekly performance of 0.24%.

Abakan Inc. (OTCMKTS:ABKI) an emerging leader in the advanced coatings and metal formulations markets, announced that it has appointed oil and gas industry veteran, Dr. Ryan Owen, PhD, to the Company’s Board of Directors. Dr. Owen has over 13 years of industry experience with BP, both domestically and internationally in upstream oil and gas, and has worked for Woods Mackenzie as a managing consultant. On last trading day company shares ended up $0.720.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *